Software Daily Summary: What Happened on October 28, 2026

Anthropic sets out plans for AI in biology and medicine

Anthropic’s filing describes work beyond using AI to write code or summarize scientific papers, including systems for research and drug discovery.12 The company says Claude has helped identify a molecular machine that might become a biotechnology tool, possibly for gene editing.2

Anthropic says it wants AI to speed drug discovery, disease detection and personalized treatment, and eventually operate lab equipment, robots and other connected machinery.1 In July 2026, Anthropic introduced Claude Science, which brings together drug-discovery tools and databases. The company said it would focus some drug research on neglected diseases.1

Anthropic warns that its models could act harmfully, autonomously or in ways their developers did not intend, including by enabling cyberattacks or biological weapon design.12 The company says it uses safeguards and access programs to limit misuse while allowing beneficial uses. It argues that balancing AI’s benefits and risks may conflict with the incentives of a for-profit company.2

Also worth knowing

• 

  Anthropic plans to list on Nasdaq as ANT. The New York Times reported that it is considering raising $100 billion at a valuation of up to $2 trillion.1

• 

  Anthropic has partnerships with Novo Nordisk, Bristol Myers Squibb, AbbVie and Sanofi.1

Also published

• Caution and Pharma’s AI Adoption: Understanding the Reasons Behind Uneven Uptake Pharmaceutical Executive
• What Outcomes Digital Twins Can be Used to Predict Pharmaceutical Executive
• The Next Biopharma Revolution: Quantum Computing Pharmaceutical Executive
• 4 Questions pharma leaders can’t skip before letting AI act pharmaphorum
• Anthropic sets out its biopharma ambitions in IPO doc pharmaphorum